Crenolanib is primarily used as a targeted therapy in the treatment of certain types of cancer, particularly those involving mutations in the FLT3 (Fms-like tyrosine kinase 3) gene. It is a potent and selective inhibitor of FLT3, which is often mutated in acute myeloid leukemia (AML), making it a promising option for patients with FLT3-mutated AML. By inhibiting the activity of the FLT3 receptor, crenolanib helps to block the growth and proliferation of cancer cells, offering a more tailored approach to treatment compared to traditional chemotherapy. It is often used in patients who have relapsed or are refractory to other FLT3 inhibitors, providing an alternative therapeutic pathway. Additionally, research is ongoing to explore its efficacy in other cancers where FLT3 mutations or related signaling pathways play a role. Its targeted mechanism of action aims to improve outcomes while potentially reducing the side effects associated with broader cancer treatments.